MARKET

STSA

STSA

SATSUMA PHARMACEUTICALS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.630
-0.150
-3.14%
Pre Market: 4.630 0 0.00% 04:09 09/21 EDT
OPEN
4.700
PREV CLOSE
4.780
HIGH
4.780
LOW
4.490
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
36.11
52 WEEK LOW
4.320
MARKET CAP
80.60M
P/E (TTM)
-1.9119
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
MYO, FDX, NKLA and VERI among after-hours movers
Gainers: [[MYO]] +64.9%. [[AMCX]] +16.5%. [[INO]] +8.9%. [[FDX]] +8.8%. [[FWONA]] +8.7%.Losers: [[NKLA]] -6.1%. [[STSA]] -5.4%. [[SPWH]] -5.0%. [[VERI]] -4.5%. [[MRNS]] -3.8%.
Seekingalpha · 5d ago
Mid-Afternoon Market Update: Nasdaq Drops Over 100 Points; A-Mark Precious Metals Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.26% to 27607.31 while the NASDAQ fell 1.05% to 10805.00. The S&P also fell, dropping 0.24% to 3331.34.
Benzinga · 09/11 19:07
The Shortened Week Provides No Shortage Of Volatility
It’s been another up-and-down week for my trading account. Every day has been similarly choppy through most of the stocks I traded, but the end result from each one has been pretty different.
Benzinga · 09/11 17:12
Mid-Day Market Update: Zumiez Surges After Q2 Results; Amyris Shares Slide
Midway through trading Friday, the Dow traded up 0.66% to 27715.14 while the NASDAQ fell 0.19% to 10898.75. The S&P also rose, gaining 0.31% to 3349.60.
Benzinga · 09/11 16:03
Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers
Gainers: Checkpoint Therapeutics (CKPT) +29%, Nano-X Imaging (NNOX) +21%, Biofrontera AG (BFRA) +20%, Zymeworks (ZYME) +14%, MEI Pharma (MEIP) +12%.Losers: Evofem Biosciences (EVFM) -20%, Satsuma Pharmaceuticals (STSA) -11%, Corbus Pharmaceuticals Holdings (CRBP) -10%, Savara (SVRA) -9%, BiondVax Pharmaceuticals (BVXV) -8%.
Seekingalpha · 09/11 15:05
Satsuma Plunges on Disappointing Data on Migraine Treatment
Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
Zacks · 09/11 14:12
ITCI, AMRS among premarket losers
Evofem Biosciences (EVFM) -14%.Amyris (AMRS) -11% after Lavvan files $881M lawsuit.Muscle Maker (GRIL) -11%.Brigham Minerals (MNRL) -10% after pricing secondary offering.Satsuma Pharmaceuticals (STSA) -7% on yesterday's news of late-stage STS101 study and analysts downgrade.Spero Therapeutics (SPRO) -8% after pricing equity
Seekingalpha · 09/11 12:21
Benzinga Pro's Top 5 Stocks To Watch For Friday, Sept. 11, 2020: NLS, FDX, POR, SFM, STSA
Today's 5 Stock Ideas:  Nautilus (NLS) - A sympathy play following strong earnings out of Peloton (PTON). Notable short seller, Andrew Left, Of Citron Research, set a $30 price target on Nautilus in
Benzinga · 09/11 12:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average STSA stock price target is 11.75 with a high estimate of 35.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 13.79M
% Owned: 79.21%
Shares Outstanding: 17.41M
TypeInstitutionsShares
Increased
21
941.57K
New
21
555.01K
Decreased
7
1.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
Heath Lukatch
President/Chief Executive Officer/Director
John Kollins
Chief Financial Officer/Primary Contact
Tom O'Neil
Vice President
Mic Iwashima
Other
Detlef Albrecht
Other
Rob Janosky
Director
Thomas Soloway
Independent Director
Thomas King
Independent Director
Michael Riebe
Independent Director
Elisabeth Sandoval
Independent Director
Rajeev Shah
Independent Director
Ken Takanashi
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average STSA stock price target is 11.75 with a high estimate of 35.00 and a low estimate of 4.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About STSA
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the treatment of migraine. The Company’s product candidate STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be self-administered with a proprietary pre-filled, single-use, nasal delivery device.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Satsuma Pharmaceuticals Inc stock information, including NASDAQ:STSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STSA stock methods without spending real money on the virtual paper trading platform.